ABOUT


Company Profile
Business Strategies

Committed to provide competitive products and services to meet unmet medical needs
Focused on the development of novel oncology drugs, anti-inflammatory drugs and other drugs.
Creating value-added strategies for clinical research to improve the value of new drugs development
With extensive experience in designing clinical trial and regulatory strategies to increase the successful rate on clinical trials and value of new drug development.
Establishing a comprehensive drug development capability from non-clinical to clinical stage and effective international collaboration
Use the rich resources from university-industry research collaboration to introduce the potential lead compounds and/or drug targets in clinical phase I locally and internationally. Improved the efficiency and success rate of drug development through drugs structure modification and optimization strategies.
Using goal orientation thinking and project management model for improving the efficiency of new drug development
Based on the target product profile and strategies in drug development, project managers can execute their projects more efficiently through the systematic management and resource coordination to manage the vendors/CROs/CMOs for accelerating new drug development times.
Management Team

Chair of Board
Dr. Yun Yen MD, PhD
Education
- Taipei Med University (MD)
- Thomas Jefferson University (PhD)
- Yale University School of Medicine (Hem Onc Fellow)
Career Experience
- 40+ years in Oncology, Cancer Therapeutics, Translational Medicine, Cancer Genomics, Academia, Philanthropy
- 80+ patents (commercialized methodologies in nanoparticles, small/large molec drugs, biomarkers, stem cells, and medical devices)
- 400+ peer reviewed publications
- Taipei Medical University (President)、City of Hope (Endowed Chair in Develop Cancer Therapeutics、Chair Molecular Pharmacology and Medical Oncology、Associate Cancer Center Director Translational Research)、Affiliate Professor of Caltech、Case Western Reserve University、Chair Professor Taipei Medical University、National Academy of Inventors、AAAS Fellow
- Business:Pharmaceutical (Co-Founder, Board, US public) 、Lixte Biopharma (Board, US public) 、Tanvex Biopharma (Chair of Board, Taiwan public) 、OBI Pharma (Board, Taiwan public)

CEO
Hui Wen Huang, EMBA

CSO
Ya Wen Cheng, PhD

Senior Manager of Business Dept.
Alice Yang, EMBA

Senior Manager of Finance Dept.
Ya Ching Yu

CEO
Hui Wen Huang, EMBA

Director of CMC Dept.
Yu-Tsai Yang, Ph.D.

Senior Manager of Business Dept.
Alice Yang, EMBA

Chief Financial Officer of Finance Dept.
Sherry Dai, MBA
Sherry received the master degree of MBA, from National Taipei University. She has worked in semiconductor companies, high-tech companies, medical materials companies, and monocrystalline silicon solar cell companies. More than 25 years of experience as a professional manager in accounting, finance, auditing and management fields.
Scientific Advisory Board

Robert B. Diasio, M.D.
Mayo Clinic Cancer Center

James Mulé, PhD
Moffitt Cancer Center

Jacqueline Whang-Peng, M.D., Ph.D.
Academician, Academia Sinica, ROC

Robert B. Diasio, M.D.
Mayo Clinic Cancer Center

James Mulé, PhD
Moffitt Cancer Center

Jacqueline Whang-Peng, M.D., Ph.D.
Academician, Academia Sinica, ROC